Alnylam Inventory Turnover vs Income Quality Analysis
ALNY Stock | USD 149.13 2.09 1.38% |
Alnylam Pharmaceuticals financial indicator trend analysis is way more than just evaluating Alnylam Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alnylam Pharmaceuticals is a good investment. Please check the relationship between Alnylam Pharmaceuticals Inventory Turnover and its Income Quality accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.
Inventory Turnover vs Income Quality
Inventory Turnover vs Income Quality Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alnylam Pharmaceuticals Inventory Turnover account and Income Quality. At this time, the significance of the direction appears to have pay attention.
The correlation between Alnylam Pharmaceuticals' Inventory Turnover and Income Quality is -0.75. Overlapping area represents the amount of variation of Inventory Turnover that can explain the historical movement of Income Quality in the same time period over historical financial statements of Alnylam Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Alnylam Pharmaceuticals' Inventory Turnover and Income Quality is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory Turnover of Alnylam Pharmaceuticals are associated (or correlated) with its Income Quality. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Quality has no effect on the direction of Inventory Turnover i.e., Alnylam Pharmaceuticals' Inventory Turnover and Income Quality go up and down completely randomly.
Correlation Coefficient | -0.75 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Most indicators from Alnylam Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 7.1 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.41 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 704.1M | 868.6M | 1.5B | 1.6B | Total Revenue | 844.3M | 1.0B | 1.8B | 1.9B |
Alnylam Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Alnylam Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alnylam Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.4B | 3.4B | 3.6B | 3.5B | 3.8B | 4.0B | |
Other Current Liab | 206.5M | 393.8M | 494.1M | 585.7M | 713.0M | 748.7M | |
Total Current Liabilities | 956.4M | 1.1B | 1.2B | 767.9M | 967.8M | 1.0B | |
Total Stockholder Equity | 1.4B | 1.0B | 588.2M | (158.2M) | (220.6M) | (209.6M) | |
Property Plant And Equipment Net | 646.4M | 706.5M | 733.6M | 738.6M | 725.8M | 762.1M | |
Net Debt | (243.4M) | 24.6M | 177.6M | 453.9M | 1.9B | 2.0B | |
Retained Earnings | (3.7B) | (4.6B) | (5.4B) | (6.6B) | (7.0B) | (6.7B) | |
Accounts Payable | 49.9M | 52.0M | 73.4M | 98.1M | 55.5M | 28.9M | |
Cash | 547.2M | 496.6M | 820.0M | 866.4M | 812.7M | 853.3M | |
Non Current Assets Total | 661.2M | 1.2B | 774.5M | 854.1M | 847.2M | 889.5M | |
Non Currrent Assets Other | 18.1M | 500M | 40.9M | 115.5M | (3.5B) | (3.4B) | |
Other Assets | 32.9M | 40.7M | 101.1M | 115.5M | 132.8M | 139.4M | |
Cash And Short Term Investments | 1.5B | 1.9B | 2.4B | 2.2B | 2.4B | 2.6B | |
Common Stock Shares Outstanding | 109.3M | 115.0M | 118.5M | 121.7M | 124.9M | 70.4M | |
Short Term Investments | 989.0M | 1.4B | 1.6B | 1.3B | 1.6B | 1.7B | |
Liabilities And Stockholders Equity | 2.4B | 3.4B | 3.6B | 3.5B | 3.8B | 4.0B | |
Non Current Liabilities Total | 603.8M | 1.3B | 1.9B | 2.9B | 3.1B | 3.2B | |
Other Current Assets | 98.4M | 90.7M | 111.9M | 132.9M | 126.4M | 68.9M | |
Total Liab | 956.4M | 2.4B | 3.1B | 3.7B | 4.1B | 4.3B | |
Property Plant And Equipment Gross | 425.2M | 706.5M | 733.6M | 738.6M | 948.9M | 996.3M | |
Total Current Assets | 1.7B | 2.2B | 2.9B | 2.7B | 3.0B | 3.1B | |
Accumulated Other Comprehensive Income | (36.5M) | (43.6M) | (33.3M) | (44.7M) | (23.4M) | (22.2M) | |
Property Plant Equipment | 425.2M | 465.0M | 502.0M | 523.5M | 602.0M | 632.1M | |
Short Long Term Debt Total | 303.8M | 521.2M | 997.6M | 1.3B | 2.7B | 2.8B | |
Other Liab | 327.7M | 352.3M | 1.4B | 406.4M | 467.3M | 490.7M | |
Current Deferred Revenue | 396.2M | 352.3M | 301.8M | 42.1M | 102.8M | 119.3M | |
Other Stockholder Equity | 5.2B | 5.6B | 6.1B | 6.5B | 6.8B | 7.2B | |
Short Term Debt | 303.8M | 329.9M | 321.9M | 42.0M | 96.5M | 67.7M | |
Net Receivables | 43.0M | 102.4M | 198.6M | 238.0M | 327.8M | 344.2M | |
Common Stock Total Equity | 1.1M | 1.2M | 1.2M | 1.2M | 1.4M | 770.9K | |
Common Stock | 1.1M | 1.2M | 1.2M | 1.2M | 1.3M | 801.6K | |
Net Tangible Assets | 1.4B | 1.0B | 588.2M | (158.2M) | (182.0M) | (172.9M) | |
Retained Earnings Total Equity | (3.7B) | (4.6B) | (5.4B) | (6.6B) | (5.9B) | (5.6B) | |
Capital Surpluse | 5.2B | 5.6B | 6.1B | 6.5B | 7.4B | 7.8B | |
Inventory | 56.3M | 92.3M | 122.7M | 129.0M | 89.1M | 93.6M | |
Non Current Liabilities Other | 603.8M | 1.6B | 1.7B | 1.5B | 1.6B | 1.7B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 15.974 | Quarterly Revenue Growth 0.548 | Return On Assets (0.03) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.